Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2171
- Registration Number
- NCT00709917
Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 747
- Registration Number
- NCT00709475
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study to Evaluate the Safety of Levemir® in Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2282
- Registration Number
- NCT00706017
- Locations
- 🇲🇽
Novo Nordisk Investigational Site, Mexico City, Mexico
Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT00705172
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 159
- Registration Number
- NCT00704574
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Lund, Sweden
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00703911
- Locations
- 🇻🇪
Novo Nordisk Investigational Site, Caracas, Venezuela
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 619
- Registration Number
- NCT00704223
Observational Study to Evaluate the Safety While Using Levemir®
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3593
- Registration Number
- NCT00701155
Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1976
- Registration Number
- NCT00700830
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 665
- Registration Number
- NCT00700817
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath